An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia (BELIEVE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02604433
Recruitment Status : Active, not recruiting
First Posted : November 13, 2015
Last Update Posted : June 7, 2018
Acceleron Pharma, Inc.
Information provided by (Responsible Party):

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Actual Primary Completion Date : November 24, 2017
  Estimated Study Completion Date : June 7, 2025
  Certification/Extension First Submitted : May 23, 2018